What Intravacc does

Intravacc B.V. is a private Dutch contract development and manufacturing organization (CDMO) headquartered at Utrecht Science Park in Bilthoven, Netherlands, specializing in vaccine development and clinical-scale manufacturing for biotech and pharmaceutical clients. The company operates four proprietary technology platforms — Vero cell-based viral vaccine production (in use since 1987), Outer Membrane Vesicle (OMV), Conjugation, and E.coli expression — and offers integrated services spanning vaccine design, upstream and downstream process development from 5mL to 200L bioreactor scale, analytical method development, and cGMP manufacturing for Phase I/II clinical supply. Its 230 sqm of Class C cleanrooms, BSL-2 capabilities, and instrumentation suite (LC-MS, HPLC, NMR, qPCR, ELISA, biosensors) support viral, bacterial, conjugate, subunit, and protein-based vaccine candidates.

Intravacc's commercial model is project-based fee-for-service CDMO work, with multi-year contracts negotiated per program by a dedicated business development team. The company primarily serves biotech and pharmaceutical companies seeking external vaccine expertise, and has historically licensed or transferred technology to vaccine manufacturers globally — with approximately 30% of childhood disease vaccines worldwide underpinned by Intravacc know-how, including polio, measles, DPT, Hib, and influenza programs. Notable ongoing activities include a Phase II Shigella flexnerii 2a conjugate vaccine and a CARB-X-funded gonorrhea OMV vaccine candidate.

The company is government-affiliated through its Utrecht Science Park position, has 51-100 employees, and secured non-dilutive funding from CARB-X (US$633,000 in January 2024) and prior European Union grants. Recent strategic moves in 2026 — including a partnership with SynphaBase AG, renewal of the Primrose Bio alliance, expansion of integrated analytical services, and French CIR (Crédit d'Impôt Recherche) certification for 2025-2027 — point to active commercial scaling into European biotech outsourcing. Virgil Schijns serves as Chief Scientific Officer, anchoring the senior scientific leadership.

Name

Intravacc

Legal name

Intravacc B.V.

Website

https://intravacc.nl

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

51–100 employees

Short description

Intravacc is a Dutch vaccine CDMO offering process development, analytical services, and cGMP manufacturing up to 200L for Phase I/II clinical supply. It serves biotech and pharmaceutical clients worldwide using four proprietary platforms (Vero cell, OMV, Conjugation, E.coli expression) with over 100 years of institutional vaccine expertise.

Ownership category

akta.pro rank

Product category

Vaccine Contract Development and Manufacturing (CDMO)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Medical Laboratories (621511)

SIC

Pharmaceutical Preparations (2834), Services-Testing Laboratories (8734)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

Keywords

• Vaccine CDMO services
• Contract vaccine manufacturing
• Viral vaccine development
• Conjugate vaccine platform
• CGMP clinical manufacturing

Headquarters

HQ city

Bilthoven

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Contract Development and Manufacturing (CDMO Services): Intravacc generates revenue by providing fee-for-service contract development and manufacturing services to biotech and pharmaceutical companies. Services span vaccine design, process development, analytical development, cGMP manufacturing, and regulatory support from early-stage R&D through Phase I/II clinical production. Revenue is project-based and earned as services are performed under client contracts.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Intravacc is a Dutch contract development and manufacturing organization (CDMO) providing integrated vaccine development and manufacturing services from early-stage R&D through Phase I/II clinical production. The company leverages four proprietary technology platforms (Vero cell, OMV, Conjugation, and E.coli expression) supported by process development, analytical development, and cGMP manufacturing capabilities. Services span viral, bacterial, conjugate, protein-based, and therapeutic vaccines for biotech, pharmaceutical, government, and NGO clients worldwide.

Product overview

Intravacc is a Dutch contract development and manufacturing organization (CDMO) offering a comprehensive suite of vaccine development services. The company operates four proprietary technology platforms: Cell-based Vaccine Production (Vero cells), Conjugate Vaccines, E.coli Expression, and OMV (Outer Membrane Vesicle) platforms. These platforms are supported by integrated services spanning process development (upstream/downstream processing, formulation), analytical development (LC-MS, HPLC, qPCR, ELISA, NMR, biosensor assays), and cGMP manufacturing capabilities for Phase I/II clinical production. The company develops viral, bacterial, and therapeutic vaccines, with notable product candidates including an OMV-based gonorrhea vaccine developed with CARB-X funding.

Differentiator

Problem solved

Functional benefit

Products and services

• Cell-based Vaccine Production Platform (Vero)
• Conjugate Vaccines Platform
• E.coli Expression Platform
• OMV (Outer Membrane Vesicle) Platform
• Process Development Services
• Analytical Development Services
• cGMP Manufacturing Services
• Integrated Analytical Services
• Gonorrhea Vaccine Candidate (OMV-based)
• Therapeutic Vaccines Development

Quantifiable outcome

• 30% of global childhood disease vaccines based on Intravacc know-how
• +3 more outcomes

Named customers2 records

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Three partnerships are on record, tiered core and minor.

• SynphaBase AGcoreStrategic or Co-development Partner · 15 June 2026Strategic partnership announced June 15, 2026 between Intravacc and SynphaBase AG (Swiss glycochemistry research company). The non-exclusive collaboration combines SynphaBase's synthetic oligosaccharide expertise with Intravacc's conjugation process development and GMP manufacturing capabilities to offer vaccine developers an integrated development pathway from raw material supply through clinical manufacturing. Each company promotes the other as a preferred partner for their respective services in conjugate vaccine programs.
• Primrose BiocoreStrategic or Co-development Partner · 1 June 2026Renewed strategic partnership between Intravacc and Primrose Bio (US-based biotechnology company) to enhance conjugate vaccine development and manufacturing. Under the agreement, Primrose Bio supplies its PeliCRM197 carrier protein while Intravacc provides antigen conjugation expertise and GMP production capabilities. The partnership offers third parties a complete solution from development through manufacturing, filling a gap in the vaccine industry and advancing vaccine accessibility globally.
• French Ministry of Higher Education, Research and SpaceminorStrategic or Co-development Partner · 27 May 2026Intravacc received approval from the French Ministry of Higher Education, Research and Space as a recognized private research organization under the French Research Tax Credit (CIR) framework for 2025-2027. The approval enables French biotech and pharmaceutical companies to declare qualifying R&D operations outsourced to Intravacc as eligible CIR expenses (30% tax credits on eligible R&D expenses up to EUR100 million), supporting Intravacc's partnerships with French and European vaccine innovators.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Emergent BioSolutions: US-based vaccine and biologics CDMO with established contract manufacturing services for viral and bacterial vaccines. Comparable to Intravacc in targeting biotech/pharma clients for clinical-stage vaccine manufacturing and development services.
• Halix: Dutch vaccine and biologics CDMO based in Leiden offering process development, GMP manufacturing, and aseptic fill-finish. Direct European competitor to Intravacc with comparable Phase I/II scale and viral/biologics focus.
• Wacker Biotech: German microbial fermentation CDMO offering E.coli-based process development and GMP manufacturing for vaccines and recombinant proteins. Directly overlaps Intravacc's E.coli expression platform and microbial vaccine capabilities.
• IDT Biologika: German vaccine and biopharmaceutical CDMO offering process development, GMP manufacturing, and fill-finish services from viral and bacterial platforms. Directly comparable to Intravacc as a specialist vaccine CDMO serving biotech and pharma clients with similar platform breadth.
• Bavarian Nordic: Danish-headquartered vaccine company with proprietary MVA-BN and other viral platforms plus contract manufacturing capacity. Comparable to Intravacc in platform-based vaccine development, GMP manufacturing for clinical supply, and European regulatory pedigree.

Broad incumbents

• Lonza Group: Swiss-headquartered global CDMO leader offering mammalian, microbial, and vaccine manufacturing services at commercial scale. Comparable to Intravacc in providing integrated DS/DP services for biologics including vaccines, but at far greater scale, multi-site footprint, and broader modality coverage.
• Charles River Laboratories: Global CRO/CDMO offering biologics manufacturing, microbial fermentation, and vaccine-related services. Comparable to Intravacc on E.coli expression and analytical services, though as part of a much broader discovery-to-manufacturing portfolio.
• Samsung Biologics: South Korean contract manufacturer of biopharmaceuticals including vaccines with very large-scale mammalian and microbial capabilities. Competes with Intravacc for vaccine development outsourcing but at vastly greater scale and global reach.
• Fujifilm Diosynth Biotechnologies: Large-scale biologics CDMO with viral vaccine, microbial, and mammalian capabilities. Comparable to Intravacc on platform breadth and vaccine focus, but operates at commercial manufacturing scales Intravacc cannot match.
• Catalent: Global CDMO with biologics, viral vector, and fill-finish capabilities including for vaccines. Overlaps Intravacc's integrated DS-DP offering but with substantially larger scale, multiple global sites, and broader therapeutic area coverage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@intravacc
• LinkedInlinkedin.com/company/intravacc
• Xx.com/intravacc

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Intravacc